Noninvasive Monitor of Vascular Volume Fluid Shifts
Primary Purpose
Blood Loss
Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
phonocardiographic measurement: InnoVital Systems
phonocardiographic measurement: ThinkLabs StethOne
physiological measurements: BIOPAC
physiological measurements: Masimo Radical-7
physiological measurements: CoVa Monitoring System 2
Thoracic impedance
Sponsored by
About this trial
This is an interventional basic science trial for Blood Loss focused on measuring phonocardiographic measurements
Eligibility Criteria
Lower Body Negative Pressure (LBNP) participants:
Inclusion Criteria:
- In generally good health
- Free of systemic diseases
- No contraindications to LBNP exposure.
- No prior history of cardiovascular disease
- Normal resting systolic blood pressure (SBP, 100-140 mm Hg) and diastolic blood pressure (DBP, 60-90 mm Hg).
Exclusion Criteria:
- Individuals who, after lying supine for five minutes, show a greater than 10 mm Hg drop in systolic pressure or a greater than 20 beats/minute increase in heart rate with standing during pre-enrollment evaluation
Blood draw participants:
Inclusion Criteria:
- In generally good health
- Free of systemic diseases
- No current or prior history of cardiovascular disease or cardiovascular reactive drugs
- Blood donors through the DHMC blood donation center
- Healthy volunteers
- People who are taking part in another study where about 500 ml of blood is being drawn
- Therapeutic phlebotomy patients (hemochromatosis or polycythemia vera patients)
Exclusion Criteria:
- Pregnancy
Sites / Locations
- Dartmouth Hitchcock Medical Center
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Blood draw
Arm Description
All blood draw subjects will have baseline data collected over 15 minutes. The participants with then donate blood. For 15 minutes after the blood donation, the participant will stay in place and will continue to have data collected.
Outcomes
Primary Outcome Measures
Change in cardiac cycle time intervals
Cardiac systolic and diastolic times
Change in phonographic characteristics - amplitude
Size of cardiac systolic and diastolic heart tones
Change in phonographic characteristics - frequency
Frequency content of cardiac tones
Secondary Outcome Measures
Full Information
NCT ID
NCT05080881
First Posted
September 22, 2021
Last Updated
April 21, 2023
Sponsor
Dartmouth-Hitchcock Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT05080881
Brief Title
Noninvasive Monitor of Vascular Volume Fluid Shifts
Official Title
Noninvasive Monitor of Vascular Volume Fluid Shifts
Study Type
Interventional
2. Study Status
Record Verification Date
April 2023
Overall Recruitment Status
Withdrawn
Why Stopped
Sponsor decided to close the study.
Study Start Date
December 15, 2021 (Actual)
Primary Completion Date
December 1, 2022 (Actual)
Study Completion Date
December 1, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Dartmouth-Hitchcock Medical Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
5. Study Description
Brief Summary
Blood volume measurements are a critical step in the emergency care of trauma patients. The typical approach to this is to rely on historical information, physical examination and metrics such as heart rate. There is currently no good real-time measure to track blood volume. This study investigates the use of phonocardiography (listening to the sounds made by the heart) to track changes in central blood volume.
Detailed Description
Blood draw subjects:
Participation in this study group may last up to 60 minutes. Participants will begin with a brief medical exam to determine eligibility. This will include a review of any history of cardiovascular disease and of medications. Prior to a scheduled blood draw, eligible participates will have physiological measurements taken, which may include phonocardiographic measurements, cardiac output, plethysmography (volume changes), multifrequency bioimpedance, thoracic impedance, heart rate, blood pressure, pulse oximetry, continuous non-invasive hematocrit measurement, and respiration. The phonocardiographic measurements may be taken with both a commercial and a custom-built device. These are all non-invasive measurements. After 15 minutes of baseline measurements, a blood draw will proceed normally while the physiological measurements continue. After the participant is finished donating blood, the participant will be asked to stay in place for an additional 15 minutes to continue to collect physiological data. Participants are asked not to eat or drink during the 15 minutes as this will provide better data collection. The information collected as data for this study includes: information about medical history, body measurements, and physiological measurements.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Blood Loss
Keywords
phonocardiographic measurements
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Blood draw
Arm Type
Experimental
Arm Description
All blood draw subjects will have baseline data collected over 15 minutes. The participants with then donate blood. For 15 minutes after the blood donation, the participant will stay in place and will continue to have data collected.
Intervention Type
Diagnostic Test
Intervention Name(s)
phonocardiographic measurement: InnoVital Systems
Other Intervention Name(s)
InnoVital Systems
Intervention Description
The instrument consists of one or more low-profile microphones in plastic housings with nitrile or silicon diaphragms. These sensors convert heart sounds into analog signals that will be acquired by the BIOPAC data acquisition system.
Intervention Type
Diagnostic Test
Intervention Name(s)
phonocardiographic measurement: ThinkLabs StethOne
Other Intervention Name(s)
ThinkLabs StethOne
Intervention Description
This device senses heart sounds and may be listened to using headphones and converted to an analog signal and saved using the BIOPAC data acquisition system.
Intervention Type
Diagnostic Test
Intervention Name(s)
physiological measurements: BIOPAC
Other Intervention Name(s)
BIOPAC
Intervention Description
Non-invasive blood pressure, electrocardiogram, heart rate, respiratory rate, and leg circumference - This is a commercially available device used regularly in health care settings to monitor continual blood pressure and heart rate.
Intervention Type
Diagnostic Test
Intervention Name(s)
physiological measurements: Masimo Radical-7
Other Intervention Name(s)
Masimo Radical-7
Intervention Description
A commercially available device for pulse oximetry and continuous non-invasive hematocrit measurement.
Intervention Type
Diagnostic Test
Intervention Name(s)
physiological measurements: CoVa Monitoring System 2
Other Intervention Name(s)
CoVa Monitoring System 2
Intervention Description
This device will be used for thoracic bioimpedance and other physiological measures. This is a commercially available device. It also measures ECG, heart rate, heart rate variability, estimated stroke volume, and estimated cardiac output. The study team may measure either while body bioimpedance or thoracic bioimpedance.
Intervention Type
Diagnostic Test
Intervention Name(s)
Thoracic impedance
Other Intervention Name(s)
Baxter
Intervention Description
Thoracic impedance is measured using the Starling device (https://usstarling.baxter.com/starling-system). Baxter uses a series of proprietary algorithms to infer stroke volume and cardiac output from thoracis impedance. Calculated values will be recorded, but the main variable that will be recorded is simply the temporal profile of thoracic impedance during the manipulations in each group (changing lower body negative pressure or therapeutic phlebotomy).
Primary Outcome Measure Information:
Title
Change in cardiac cycle time intervals
Description
Cardiac systolic and diastolic times
Time Frame
Through study completion; 3 hours
Title
Change in phonographic characteristics - amplitude
Description
Size of cardiac systolic and diastolic heart tones
Time Frame
Through study completion; 3 hours
Title
Change in phonographic characteristics - frequency
Description
Frequency content of cardiac tones
Time Frame
Through study completion; 3 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
49 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Lower Body Negative Pressure (LBNP) participants:
Inclusion Criteria:
In generally good health
Free of systemic diseases
No contraindications to LBNP exposure.
No prior history of cardiovascular disease
Normal resting systolic blood pressure (SBP, 100-140 mm Hg) and diastolic blood pressure (DBP, 60-90 mm Hg).
Exclusion Criteria:
Individuals who, after lying supine for five minutes, show a greater than 10 mm Hg drop in systolic pressure or a greater than 20 beats/minute increase in heart rate with standing during pre-enrollment evaluation
Blood draw participants:
Inclusion Criteria:
In generally good health
Free of systemic diseases
No current or prior history of cardiovascular disease or cardiovascular reactive drugs
Blood donors through the DHMC blood donation center
Healthy volunteers
People who are taking part in another study where about 500 ml of blood is being drawn
Therapeutic phlebotomy patients (hemochromatosis or polycythemia vera patients)
Exclusion Criteria:
Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James C Leiter, M.D.
Organizational Affiliation
Dartmouth-Hitchcock Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dartmouth Hitchcock Medical Center
City
Lebanon
State/Province
New Hampshire
ZIP/Postal Code
03756
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
There are no data to share.
Learn more about this trial
Noninvasive Monitor of Vascular Volume Fluid Shifts
We'll reach out to this number within 24 hrs